Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

42.66 +0.48 (+1.15%)
Streaming Delayed Price Updated: 11:28 AM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
42 43 Next >
We Asked Retail Traders About Eli Lilly’s Biggest Post-Q4 Risk — Most Say It’s The Weight-Loss Drug Wars
Lilly’s fiercest competitor in the obesity market is Novo Nordisk, which offers Ozempic and Wegovy. However, rising threats from other players such as Hims & Hers, Amgen, and Viking Therapeutics also... 
Via Stocktwits
Hims & Hers Launches Health Collective and Community Member Council
From Hims & Hers
Via Business Wire
Hims & Hers to Announce Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
From Hims & Hers
Via Business Wire
Hims & Hers Health Unusual Options Activity For February 03
 
Via Benzinga
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio?
Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following positive clinical trial results and other companies like Surgery Partners... 
Via Benzinga
Unlocking the Growth Potential of NYSE:HIMS.
A fundamental analysis of (NYSE:HIMS): Is HIMS & HERS HEALTH INC (NYSE:HIMS) suited for growth investing? 
Via Chartmill
Is Hims & Hers Health Stock a Buy?
Here's a look into one of healthcare's hottest growth stocks. 
Via The Motley Fool
Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions 
Via MarketBeat
Hims & Hers Health Unusual Options Activity
 
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Hims & Hers Health: A Stock to Trade or Own?
HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors. 
Via MarketBeat
Why the high growth investor may take a look at NYSE:HIMS.
Unlocking the high Growth Potential of HIMS & HERS HEALTH INC (NYSE:HIMS). 
Via Chartmill
Is Hims & Hers Stock in Trouble?
Via The Motley Fool
Evaluating NYSE:HIMS for Growth Investment Opportunities.
Is HIMS & HERS HEALTH INC (NYSE:HIMS) suited for growth investing? 
Via Chartmill
What 12 Analyst Ratings Have To Say About Hims & Hers Health
 
Via Benzinga
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
Via The Motley Fool
Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025 
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Hims & Hers Stock Is Poised for a Major Surge in 2025
The focus is on GLP-1s, but there's more to Hims & Hers than one product. 
Via The Motley Fool
What's Going On With Hims & Hers Health Stock?
Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst expectations. 
Via Benzinga
Stock Picks 2024 Year In Review
Unlike 2023, 2024 was a very concentrated year, with just a few key large-cap stocks driving much of the index's returns. 
Via Talk Markets
Topics Stocks / Equities
Is Hims & Hers Health a Millionaire Maker?
Arguments are piling up for why the company might fail, but the business continues to deliver strong results. 
Via The Motley Fool
3 Hot Stocks That Can Double Again in 2025
Three unlikely winners of 2024 can lead the way in the year ahead. 
Via The Motley Fool
Prediction: This Will Be Amazon's Next Big Acquisition
Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm over the last several years. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Will The Falling Hims & Hers Stock Price Recover In 2025?
Hims & Hers share price has crashed by over 20% this year after an unfavorable FDA ruling. 
Via Talk Markets
Topics Stocks / Equities
Hims & Hers Stock: Growth, Noise, and Where to Focus Now
Hims & Hers stock is full of noise, but what's the signal for investors? 
Via The Motley Fool
Hims & Hers Health Are Falling Today: What's Going On?
Hims & Hers Health, Inc. (NYSE: HIMS) are trading lower Thursday. The U.S. Food and Drug Administration (FDA) issued a new decision regarding the status of tirzepatide injection shortages, which have... 
Via Benzinga
From Powell To Profits: Strategic Stock Picks Amid Market Uncertainty
Yesterday's market movement aligned perfectly with expectations, as the FOMC meeting drove significant volatility. 
Via Talk Markets
Topics Stocks / Equities
IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List
Compounders now have until late March to wind down their operations, depending on their licensing. 
Via Investor's Business Daily
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.